Exploratory analysis of how real world evidence influences treatment decisions in lower income European countries, suggesting improved health technology assessments.
This is the first study to explore how RWE generated by the TTE method can be transferred to optimize treatment decisions of patients with a rare disease in countries with limited HTA capacities. Five general concluding statements were made on the novelty of the TTE method and on how to overcome main challenges of transferring TTE results to HTA systems in LIECs.
No takes yet. Share an insight, caveat, or question.
Kaló et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: